{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-017501","form_type":"8-K","ticker":"IRMD","cik":"0001325618","company_name":"IRADIMED CORP","filed_at":"2023-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.605273+00:00","generated_at":"2026-06-08T22:09:15.535242+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Iradimed reports record Q3 revenue $16.5M, raises FY GAAP EPS guidance to $1.34-$1.37","bullets":["Q3 revenue $16.5M (+23% YoY); GAAP diluted EPS $0.40 vs $0.27 YoY; non-GAAP diluted EPS $0.43 vs $0.29 YoY.","Operating income $5.9M, up 43% YoY; ninth consecutive quarterly revenue record led by monitoring business up 40% QoQ.","Q4 2023 guidance: revenue $16.9M-$17.4M; GAAP EPS $0.35-$0.38; non-GAAP EPS $0.38-$0.41.","Full-year 2023 guidance raised: revenue $65.0M-$65.5M; GAAP EPS $1.34-$1.37 (up from prior); non-GAAP EPS $1.48-$1.51.","Cash flow from operations $3.5M in Q3 ($9.6M YTD) vs $2.4M ($7.0M YTD) YoY."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-017501","json":"https://secwatch.observer/filing/0001558370-23-017501.json","markdown":"https://secwatch.observer/filing/0001558370-23-017501.md","text":"https://secwatch.observer/filing/0001558370-23-017501.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1325618/000155837023017501/0001558370-23-017501-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1325618/000155837023017501/irmd-20231103x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T22:09:15.535242+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"803ae173239f75410695a5bb06819c02ce9aff7a","claim":"IRADIMED CORP reported nine months ended September 30, 2023 results: net income $14.0 million, EPS $1.1.","evidence_excerpt":"For the nine months ended September 30, 2023, the Company reported revenue of $48.1 million compared to $38.4 million for the same period of 2022. Net income was $12.7 million, or $0.99 per diluted share, compared to $9.2 million, or $0.72 per diluted share for the same period of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1325618/000155837023017501/0001558370-23-017501-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"nine months ended September 30, 2023"},{"label":"Net income","value":"$14.0 million"},{"label":"EPS","value":"$1.1"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"803ae173239f75410695a5bb06819c02ce9aff7a","claim":"IRADIMED CORP reported nine months ended September 30, 2023 results: net income $14.0 million, EPS $1.1.","evidence_excerpt":"Non-GAAP net income was $14.0 million, or $1.1 per diluted share, for the nine months ended September 30, 2023, and excludes $1.3 million of stock compensation expense, net of tax expense.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1325618/000155837023017501/0001558370-23-017501-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"nine months ended September 30, 2023"},{"label":"Net income","value":"$14.0 million"},{"label":"EPS","value":"$1.1"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"813aeab5c7ef8e9d763ee77ed9acde83522c04e3","claim":"IRADIMED CORP reported fourth quarter 2023 results: EPS $0.38 to $0.41. Guidance initiated.","evidence_excerpt":"For the fourth quarter of 2023, the Company expects to report revenue of $16.9 million to $17.4 million, GAAP diluted earnings per share of $0.35 to $0.38, and non-GAAP diluted earnings per share of $0.38 to $0.41.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1325618/000155837023017501/0001558370-23-017501-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter 2023"},{"label":"EPS","value":"$0.38 to $0.41"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"a9e51ae8277365806752b2d85fddc287ea27ff5b","claim":"IRADIMED CORP reported third quarter ended September 30, 2023 results: net income $5.5 million, EPS $0.43.","evidence_excerpt":"For the third quarter ended September 30, 2023, the Company reported over 23% year-over-year revenue growth to $16.5 million compared to $13.4 million for the third quarter of 2022. Net income was $5.1 million, or $0.40 per diluted share, compared to $3.4 million, or $0.27 per diluted share for the third quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1325618/000155837023017501/0001558370-23-017501-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Net income","value":"$5.5 million"},{"label":"EPS","value":"$0.43"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"a9e51ae8277365806752b2d85fddc287ea27ff5b","claim":"IRADIMED CORP reported third quarter ended September 30, 2023 results: net income $5.5 million, EPS $0.43.","evidence_excerpt":"Non-GAAP net income was $5.5 million, or $0.43 per diluted share, for the quarter ended September 30, 2023, and excludes $0.4 million of stock compensation expense, net of tax expense.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1325618/000155837023017501/0001558370-23-017501-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Net income","value":"$5.5 million"},{"label":"EPS","value":"$0.43"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"e6257e386cdf5524460f2372945be1b18fa5086c","claim":"IRADIMED CORP reported full-year 2023 results: EPS $1.48 to $1.51. Guidance raised.","evidence_excerpt":"For the full-year 2023 financial guidance, the Company now expects to report revenue of $65.0 million to $65.5 million, GAAP diluted earnings per share of $1.34 to $1.37, and non-GAAP diluted earnings per share of $1.48 to $1.51.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1325618/000155837023017501/0001558370-23-017501-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full-year 2023"},{"label":"EPS","value":"$1.48 to $1.51"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}